News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

UV Flu Technologies Inc. Subsidiary Introduces RX6500 Air Purifier Designed for Counter-Bioterrorism Market


4/19/2011 9:12:35 AM

CENTERVILLE, MA--(Marketwire - April 19, 2011) - UV Flu Technologies, Inc. (OTCBB: UVFT) (the "Company") announced today that its wholly-owned subsidiary, Rx Air Industries, LLC, ("RxAir") headquartered in Dallas, Texas, has introduced the RX-6500, an air filtration system specifically designed for Homeland Security applications.

The RX6500 features include an airflow of 2,500cfm, ozone free germicidal UV, micro-processor with data port for remote monitoring and alarm codes, and HEPA filtration systems that removes 99.97% of contaminants greater than 0.3 microns. The unit also has a chemical adsorption filtration pack specifically designed for military applications, providing protection against cyanogens chloride (CK), Sarin (GB), hydrogen cyanide (AC), and industrial gases such as chlorine. The unit can also create and maintain an isolation environment in a shelter up to 2,000 sq. feet, such as a mobile hospital or command center, up to required standards as proposed by the CDC.

RxAir (www.rxair.com) is a well-known and highly regarded manufacturer of high quality air purification equipment designed for applications within the medical and hospitality marketplace, and also includes products geared for specialized industrial applications, such as emergency preparedness. The RX6500 was one of three products included in the acquisition of the Company by UV Flu Technologies, but was never previously marketed due to capital constraints. The Company's two main products, the RX3000, which is the Company's best seller, provides air purification coverage in spaces up to 2000 sq. ft, while the RX4500, also known as the "Smoke Handler," is the preferred choice of hospitality establishments nationwide, and in a system of 2 units can protect spaces of up to 20,000 sq. feet, and can be connected to existing ductwork. Both units can remove more than 99.97% of airborne contaminants and pathogens greater than 0.3 micrometers in size, and are designed with exterior cabinetry able to match any décor.

"The RX6500 not only opens up huge new markets to us, it illustrates our capability to design, or alter our products for almost any application involving air purification," said Jack Lennon, President of UV Flu Technologies. "Given that RxAir products are manufactured here in the United States, we are taking steps to become eligible for bidding on military, as well as other government contracts. With all of the unrest in the World today, having a product that can clear a space up to 2,000 sq. ft, from poisonous or toxic gasses within minutes is an important tool to keep our citizens safe, whether from a terrorist threat, pandemic, or an industrial accident. Government or military buildings, schools, control rooms or hospitals are all potential markets for our products. Through continuous testing and product improvement, we plan to become recognized innovators in this multi-billion dollar air quality sector."

Further details regarding the Company's business, acquisitions, financial reports and agreements are filed as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, visit: www.uvflutech.com.

About UV Flu Technologies, Inc. (OTCBB: UVFT)
UV Flu Technologies is an innovative developer, manufacturer and distributor of bio technology products initially targeting the rapidly growing Indoor Air Quality ("IAQ") industry sector (over $7.7 billion in 2008). The Company manufactures the ViraTech UV-400, which utilizes high-intensity ultraviolet radiation (UV-C) inside a killing chamber that goes beyond filtration to destroy harmful airborne bacteria, at rates exceeding 99.2% on a first-pass basis, while also reducing the concentrations of odors, and VOC's (volatile organic compounds, such as acetone, benzene, formaldehyde, etc.) The FDA has issued a coveted Class II medical listing that enables UV Flu Technologies to market the product as a medical device. For more information, visit: www.uvflutech.com.

Notice Regarding Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

UV Flu Technologies, Inc.
-----------------------------
John J. Lennon, President & CEO


Investor Information:
Geaux IR Services, Inc.
Toll-Free: 1-888-355-8838
investors@uvflutech.com
Web: www.uvflutech.com

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES